CLSI MM14
Design of Molecular Proficiency Testing/ External Quality Assessment; Approved Guideline
| Organization: | CLSI |
| Publication Date: | 1 May 2013 |
| Status: | inactive |
| Page Count: | 84 |
scope:
The purpose of this guideline is to complement currently
available regulatory and guidance documents regarding the
management and operations of proficiency testing/external quality
assessment (PT/EQA) programs. Presently, these documents guide the
administration of such programs, but consideration of panel
selection, analysis of data for evolving technologies and tests
with many possible measurands, method-based PT/EQA, and reporting
to participants are not addressed. For molecular methods, these
issues are important for all stakeholders, including regulatory
agencies, accrediting agencies, PT/EQA providers/organizati
This guideline does not address the process of testing and reporting PT/EQA in the medical laboratory, medical laboratory inspection, accreditation, or other regulatory processes.
This guideline focuses on nucleic acid (DNA and RNA) PT in the areas of human genetics, infectious disease, molecular oncology, and pharmacogenetics. Though written specifically to address needs in this area, the principles stated may be applicable to programs outside of nucleic acid testing.
Organizations and programs that send blinded samples to
laboratories and analyze the submitted results carry several
different names. These challenge programs may be called PT/EQA,
quality assessment or assurance programs, QC programs, ring trials,
sample exchange, and EQA/assurance. Countries or regions may place
regulatory distinctions on these names. To facilitate the
readability of this document, the terms PT/EQA, PT/EQA
provider/organizatio
Document History